Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US-9220776-B2 · Dec 29, 2015 · US
Antibodies to human programmed death receptor PD-1
US9834605B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9834605-B2 |
| Application number | US-201414576448-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2014 |
| Priority date | Jun 18, 2007 |
| Publication date | Dec 5, 2017 |
| Grant date | Dec 5, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
First claim
Opening claim text (preview).
We claim: 1. An isolated polynucleotide encoding an antibody or antibody fragment which binds to human programmed death receptor 1 (PD-1), wherein the antibody or antibody fragment comprises a. three light chain CDRs having the amino acid sequences set forth in SEQ ID NOs:15, 16 and 17; and/or b. three heavy chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 18, 19 and 20. 2. The isolated polynucleotide of claim 1 , which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 21, 22, 23, 24, and 27. 3. An expression vector comprising the polynucleotide of claim 1 . 4. An isolated host cell comprising the expression vector of claim 3 . 5. A method of producing an antibody or antibody fragment that binds to human programmed death receptor 1 (PD-1) comprising: a. culturing a host cell in culture medium, wherein the host cell comprises the polynucleotide of claim 1 and wherein the host cell is cultured under conditions wherein the antibody or antibody fragment is expressed; and b. recovering the antibody or antibody fragment from the host cell or culture medium. 6. The isolated polynucleotide of claim 1 , wherein the antibody or antibody fragment comprises a light chain variable region comprising amino acid residues 20 to 130 of SEQ ID NO:32 and a heavy chain variable region comprising amino acid residues 20 to 139 of SEQ ID NO:30. 7. The isolated polynucleotide of claim 6 , wherein the antibody or antibody fragment comprises a light chain comprising amino acid residues 20 to 237 of SEQ ID NO:36 and a heavy chain comprising amino acid residues 20 to 466 of SEQ ID NO:31. 8. An expression vector comprising the polynucleotide of claim 6 . 9. An isolated host cell comprising the expression vector of claim 8 .
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Immunostimulants · CPC title
involving compounds identifiable in body fluids · CPC title
IL-2 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9834605B2 cover?
- Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
- Who is the assignee on this patent?
- Merck Sharp & Dohme, Merck Sharpe & Dohme B V
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2818. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).